Shedding of infectious SARS-CoV-2 despite vaccination.
Journal
PLoS pathogens
ISSN: 1553-7374
Titre abrégé: PLoS Pathog
Pays: United States
ID NLM: 101238921
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
received:
12
11
2021
accepted:
12
09
2022
revised:
12
10
2022
pubmed:
1
10
2022
medline:
15
10
2022
entrez:
30
9
2022
Statut:
epublish
Résumé
The SARS-CoV-2 Delta Variant of Concern is highly transmissible and contains mutations that confer partial immune escape. The emergence of Delta in North America caused the first surge in COVID-19 cases after SARS-CoV-2 vaccines became widely available. To determine whether individuals infected despite vaccination might be capable of transmitting SARS-CoV-2, we compared RT-PCR cycle threshold (Ct) data from 20,431 test-positive anterior nasal swab specimens from fully vaccinated (n = 9,347) or unvaccinated (n = 11,084) individuals tested at a single commercial laboratory during the interval 28 June- 1 December 2021 when Delta variants were predominant. We observed no significant effect of vaccine status alone on Ct value, nor when controlling for vaccine product or sex. Testing a subset of low-Ct (<25) samples, we detected infectious virus at similar rates, and at similar titers, in specimens from vaccinated and unvaccinated individuals. These data indicate that vaccinated individuals infected with Delta variants are capable of shedding infectious SARS-CoV-2 and could play a role in spreading COVID-19.
Identifiants
pubmed: 36178969
doi: 10.1371/journal.ppat.1010876
pii: PPATHOGENS-D-21-02286
pmc: PMC9555632
doi:
Substances chimiques
COVID-19 Vaccines
0
Viral Vaccines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1010876Subventions
Organisme : NHGRI NIH HHS
ID : T32 HG002760
Pays : United States
Déclaration de conflit d'intérêts
I have read the journal’s policy and the authors of this manuscript have the following competing interests: Amanda Kita-Yarbro owns 25 shares of Pfizer stock. The other authors have declared that no competing interests exist.
Références
Lancet. 2022 Mar 5;399(10328):924-944
pubmed: 35202601
J Med Virol. 2022 Jul;94(7):3192-3202
pubmed: 35307848
Nat Microbiol. 2022 May;7(5):640-652
pubmed: 35484231
Braz J Microbiol. 2022 Sep;53(3):1271-1277
pubmed: 35446012
Science. 2022 Jan 07;375(6576):43-50
pubmed: 34812653
Lancet Respir Med. 2022 Jul;10(7):689-699
pubmed: 35468336
Sci Rep. 2022 Apr 28;12(1):6568
pubmed: 35484176
PLoS Biol. 2020 Sep 8;18(9):e3000849
pubmed: 32898168
J Occup Environ Med. 2021 Apr 1;63(4):291-295
pubmed: 33315723
Biomedicines. 2022 Feb 01;10(2):
pubmed: 35203547
JMIR Public Health Surveill. 2022 May 12;8(5):e29343
pubmed: 35377319
Vaccines (Basel). 2022 Mar 23;10(4):
pubmed: 35455241
BMJ. 2022 Mar 9;376:e069761
pubmed: 35264324
Vaccines (Basel). 2022 Mar 29;10(4):
pubmed: 35455280
Pediatr Infect Dis J. 2020 Dec;39(12):e388-e392
pubmed: 33031141
MMWR Morb Mortal Wkly Rep. 2021 May 14;70(19):719-724
pubmed: 33988185
N Engl J Med. 2020 Nov 12;383(20):1920-1931
pubmed: 32663912
Lancet Reg Health Am. 2022 May;9:100212
pubmed: 35229081
JAMA Pediatr. 2020 Sep 1;174(9):902-903
pubmed: 32745201
J Med Virol. 2022 Sep 29;:
pubmed: 36176180
Euro Surveill. 2021 Sep;26(39):
pubmed: 34596015
Nat Med. 2021 Dec;27(12):2127-2135
pubmed: 34650248
Clin Microbiol Infect. 2022 Apr;28(4):612.e1-612.e7
pubmed: 34826623
Nature. 2020 May;581(7809):465-469
pubmed: 32235945
JCI Insight. 2022 Jan 25;7(2):
pubmed: 34871181
Int J Epidemiol. 2022 Jan 6;50(6):1795-1803
pubmed: 34999848
Clin Infect Dis. 2022 Aug 15;75(Supplement_1):S61-S71
pubmed: 35607747
N Engl J Med. 2021 Dec 23;385(26):2489-2491
pubmed: 34941024
Vaccine. 2022 May 3;40(20):2841-2847
pubmed: 35397946
N Engl J Med. 2020 May 28;382(22):2081-2090
pubmed: 32329971
Vaccines (Basel). 2022 Feb 17;10(2):
pubmed: 35214779
N Engl J Med. 2022 Feb 24;386(8):744-756
pubmed: 34986294
Front Med (Lausanne). 2021 Jan 27;8:608215
pubmed: 33585523
N Engl J Med. 2022 Mar 10;386(10):933-941
pubmed: 35020982
PLoS One. 2021 Jul 14;16(7):e0254456
pubmed: 34260633
MMWR Morb Mortal Wkly Rep. 2021 Jun 11;70(23):858-864
pubmed: 34111059
N Engl J Med. 2021 Oct 14;385(16):1474-1484
pubmed: 34320281
J Med Virol. 2022 Aug;94(8):3978-3981
pubmed: 35355294
Front Immunol. 2022 Mar 02;13:842912
pubmed: 35309363
N Engl J Med. 2021 May 13;384(19):1824-1835
pubmed: 33440088
N Engl J Med. 2020 Dec 17;383(25):2439-2450
pubmed: 33053279
Euro Surveill. 2020 Aug;25(32):
pubmed: 32794447
J Infect Dis. 2021 Dec 1;224(11):1821-1829
pubmed: 34647601
Diabetes Ther. 2022 May;13(5):1037-1051
pubmed: 35416588